Assembly Biosciences (NASDAQ:ASMB) Given “Buy” Rating at Guggenheim

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They currently have a $43.00 price objective on the biopharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 58.53% from the company’s current price.

ASMB has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Finally, Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Assembly Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

Assembly Biosciences Stock Performance

Assembly Biosciences stock opened at $27.13 on Thursday. The company has a market capitalization of $431.10 million, a price-to-earnings ratio of -246.52 and a beta of 1.08. The stock has a fifty day moving average of $28.57 and a two-hundred day moving average of $30.40. Assembly Biosciences has a fifty-two week low of $13.70 and a fifty-two week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The firm had revenue of $8.21 million during the quarter, compared to the consensus estimate of $9.27 million. On average, analysts forecast that Assembly Biosciences will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the stock. Commodore Capital LP acquired a new position in Assembly Biosciences in the third quarter worth $25,600,000. Farallon Capital Management LLC acquired a new stake in shares of Assembly Biosciences during the third quarter worth $31,426,000. Patient Square Capital LP acquired a new stake in shares of Assembly Biosciences during the third quarter worth $3,461,000. Palumbo Wealth Management LLC lifted its position in shares of Assembly Biosciences by 86.4% in the 3rd quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 16,131 shares during the last quarter. Finally, Stempoint Capital LP lifted its position in shares of Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after buying an additional 28,707 shares during the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.